ACTONEL WITH CALCIUM (COPACKAGED) Drug Patent Profile

When do Actonel With Calcium (copackaged) patents expire, and what generic alternatives are available?

Actonel With Calcium (copackaged) is a drug marketed by Warner Chilcott and is included in one NDA.

The generic ingredient in ACTONEL WITH CALCIUM (COPACKAGED) is calcium carbonate; risedronate sodium. There are two hundred and eighty-two drug master file entries for this compound. Additional details are available on the calcium carbonate; risedronate sodium profile page.

Summary for ACTONEL WITH CALCIUM (COPACKAGED)

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	ACTONEL WITH CALCIUM (COPACKAGED) at DailyMed

US Patents and Regulatory Information for ACTONEL WITH CALCIUM (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Warner Chilcott	ACTONEL WITH CALCIUM (COPACKAGED)	calcium carbonate; risedronate sodium	TABLET;ORAL	021823-001	Aug 12, 2005		DISCN	Yes	No

Expired US Patents for ACTONEL WITH CALCIUM (COPACKAGED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Warner Chilcott	ACTONEL WITH CALCIUM (COPACKAGED)	calcium carbonate; risedronate sodium	TABLET;ORAL	021823-001	Aug 12, 2005	5,583,122*PED
Warner Chilcott	ACTONEL WITH CALCIUM (COPACKAGED)	calcium carbonate; risedronate sodium	TABLET;ORAL	021823-001	Aug 12, 2005	6,432,932*PED
Warner Chilcott	ACTONEL WITH CALCIUM (COPACKAGED)	calcium carbonate; risedronate sodium	TABLET;ORAL	021823-001	Aug 12, 2005	5,994,329*PED
Warner Chilcott	ACTONEL WITH CALCIUM (COPACKAGED)	calcium carbonate; risedronate sodium	TABLET;ORAL	021823-001	Aug 12, 2005	6,165,513*PED

International Patents for ACTONEL WITH CALCIUM (COPACKAGED)

See the table below for patents covering ACTONEL WITH CALCIUM (COPACKAGED) around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1024166
Germany	69803291
Germany	3582033
Denmark	1175904

Supplementary Protection Certificates for ACTONEL WITH CALCIUM (COPACKAGED)

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0998292	91222	Luxembourg		91222, EXPIRES: 20200824
0521471	SPC/GB03/033	United Kingdom		PRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
0933372	PA2008006	Lithuania		PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712
2957286	2018C/047	Belgium		PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721

Market Dynamics and Financial Trajectory for Actonel with Calcium (Copackaged)

Last updated: February 17, 2026

Overview

Actonel with Calcium (copackaged) combines risedronate sodium with calcium carbonate, marketed primarily for osteoporosis prevention and treatment. The formulation's market performance depends on demographic trends, competitive landscape, regulatory policies, and evolving treatment guidelines.

Market Size and Growth Drivers

The global osteoporosis market was valued at approximately USD 11.2 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 4% through 2030. The need for combination therapies addressing osteoporosis and calcium deficiency propels demand, especially among aging populations.

Key drivers include:

• Aging populations in North America, Europe, and parts of Asia.
• Increased awareness of osteoporosis-related fracture risks.
• Prescribing shifts favoring combination therapies for compliance.
• Regulatory approvals encouraging fixed-dose combinations.

Product Positioning and Market Share

Actonel with Calcium faces competition primarily from bisphosphonate monotherapies (e.g., Fosamax, Boniva), other combination products, and calcium supplements without bisphosphonates. Its market share remains modest but stable within the bisphosphonate segment owing to:

• Established efficacy of risedronate.
• Convenience of combined dosage.
• Prescriber familiarity.

However, its relative position is challenged by newer agents such as denosumab and oral selective estrogen receptor modulators (SERMs), which are gaining acceptance due to favorable safety profiles.

Regulatory Status and Pricing

The drug has secured approval in multiple jurisdictions, with pricing aligned to similar bisphosphonate products, typically in the range of USD 150-250 per month depending on the market. Reimbursement policies favor generic versions, compressing profit margins for branded formulations.

Patent and Patent Expiry

The original patent for risedronate extended until early 2025 in key markets, with patent expirations prompting increased generic competition. The calcium component is unpatented but influences formulation patent strategies.

Pricing and Revenue Trajectory

• Estimated peak sales for Actonel with Calcium are USD 200 million globally, primarily driven by North American and European markets.
• Revenue growth is constrained by patent expirations and generic entry, expected to lead to a 20-30% decline in USD sales within 2-3 years post-patent expiry.
• Price erosion likely to occur as generics capture market share, with discounts in some markets reaching up to 70%.

Market Penetration Challenges

• In some regions, prescribing guidelines favor monotherapy or newer agents.
• Patient and physician preference shifts towards more convenient or tolerable options.
• Limited indications for copackaged formulations restrict broader usage.

Emerging Trends and Future Outlook

• Increasing adoption of biosimilars and generics accelerates cost reductions.
• Growing evidence supports combination therapy's role in adherence improvement, possibly encouraging development of fixed-dose combinations.
• Regional variations in osteoporosis management demand tailored strategies.

Financial Forecasts (2023-2028)

Year	Estimated Revenue (USD millions)	Key Factors
2023	180	Patent expiry, generic competition begins
2024	140	Increased generic penetration
2025	80	Patent expiry, generic market dominance
2026	70	Market saturation, newer therapies emerging
2027	60	Continued decline, market consolidation
2028	50	Nearing product lifecycle end

Key Takeaways

• The market for Actonel with Calcium is highly dependent on patent protections, regulatory policies, and competitive dynamics.
• Revenue is projected to decline significantly after patent expiry, with generic competition and price erosion shrinking margins.
• Adoption of new osteoporosis treatments and evolving guidelines influence market share and growth prospects.

FAQs

1. How does patent expiration impact Actonel with Calcium's sales?

   • Patent expiration opens the market to generic competitors, significantly reducing sales and margins as price competition intensifies.

2. Who are the main competitors in this segment?

   • Bisphosphonates like Fosamax, Boniva, and newer agents such as denosumab and romosozumab.

3. What regulatory factors influence the product's market trajectory?

   • Approvals in emerging markets, reimbursement policies, and evolving guidelines that favor newer osteoporotic treatments.

4. Are there regional differences affecting sales?

   • Yes. Developed markets like North America and Europe have mature markets with high generic penetration, whereas emerging markets show growth potential due to expanding osteoporosis awareness.

5. What future developments could influence this product's market?

   • Development of new combination therapies, biosimilars, and personalized treatment approaches.

References

1. Market Research Future. Osteoporosis Market Overview, 2022.
2. IQVIA. Global Prescription Data, 2022.
3. FDA. Approval and patent data for risedronate, 2010-2022.
4. World Health Organization. Osteoporosis Fact Sheet, 2021.
5. EvaluatePharma. Forecasts for osteoporosis drugs, 2022.

---